Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2000 Mar 16;46(1):127–137. doi: 10.1016/0165-2427(94)07012-V

Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection

R Hofmann-Lehmann a,∗, E Holznagel a, A Aubert b, P Ossent c, M Reinacher d, H Lutz a
PMCID: PMC7119625  PMID: 7618252

Abstract

The efficacy and the long-term protection of a recombinant feline leukemia virus (FeLV) vaccine were determined in 30 specified pathogen free cats for over 3 years. At the same time, in order to specify the effects of feline immunodeficiency virus (FIV) on the immune system, one half of the cats (n = 15) were previously infected with the Swiss isolate FIV Zurich 2. The second half of the animals (n = 15) served as non-infected controls. Eighteen (nine FIV-negative, nine FIV-positive) vaccinated and 12 (six FIV-negative, six FIV-positive) non-vaccinated cats were intraperitoneally challenged with FeLV A. Seventeen of 18 vaccinated cats were protected against persistent viremia, while ten of 12 non-vaccinated controls became infected. An increase of antibodies against FeLV SU was found in all protected cats after the challenge exposure. No difference in vaccine efficacy was found between FIV-negative and FIV-positive animals.

The whole group of cats was observed for over 3 years. There were no further vaccinations during this period. CD4+ and CD8+ cell subsets, clinical outcome and time of survival of the cats were recorded. FIV-negative and FIV-positive animals were kept in two different rooms. However, FeLV-negative and FeLV viremic cats were housed together in both rooms in order to imitate a natural FeLV exposure situation. Anti-recombinant FeLV SU antibodies were measured by enzyme-linked immunosorbent assay. Although a continuous decline of antibodies was found in FeLV vaccinated cats, they remained protected against constant FeLV challenge for over 3 years. FIV infection had a stronger effect on the depression of the CD4+:CD8+ ratio than FeLV infection. Within the group of FIV-positive cats, the FeLV-vaccinated animals had significantly better survival rates as well as better clinical and laboratory parameters. FIV- and FeLV-coinfected cats showed the lowest CD4+:CD8+ ratio, mainly caused by decreased CD4+ lymphocyte counts. CD8+ lymphocytes with strong fluorescence (CD8high) disappeared and cells with weak fluorescence (CD8low) appeared instead. Prevention of coinfection by immunizing FIV-positive cats against FeLV infection improved the clinical outcome and prolonged the cat's life expectancy.

Abbreviations: ELISA, enzyme-linked immunosorbent assay; FeLV, feline leukemia virus; FIV, feline immunodeficiency virus; SPF, specified pathogen free

References

  1. Barlough J.E., Ackley C.A., George J.W., Levy N., Acevedo R., Moore P.F., Rideout B.A., Cooper M.D., Pedersen N.C. Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J. AIDS. 1991;4:219–227. [PubMed] [Google Scholar]
  2. Clark N., Kushner N.N., Barrett C.B., Kensil C.R., Salsbury D., Cotter S. Efficacy and safety trial of a recombinant DNA vaccine against feline leukemia virus infection. J. Am. Vet. Med. Assoc. 1991;199:1433–1443. [PubMed] [Google Scholar]
  3. Hardy W.D. Feline leukemia virus disease. In: Hardy W.D., Essex M., McClelland A.J., editors. Elsevier; Amsterdam: 1980. pp. 3–31. (Developments in Cancer Research, Vol. 4, Feline Leukemia Virus). [Google Scholar]
  4. 4.Holznagel, E., Hofmann-Lehmann, R., Niederer, E. and Lutz, H. Improved method for flow cytometric analysis of feline leukocytes. J. Immunol. Methods, submitted for publication.
  5. Ishida T., Tomoda I. Clinical staging of feline immunodeficiency virus infection. Jpn. J. Vet. Sci. 1990;52:645–648. doi: 10.1292/jvms1939.52.645. [DOI] [PubMed] [Google Scholar]
  6. Ishida T., Taniguchi A., Matsumura S., Washizu T., Tomoda I. Long-term clinical observations on feline immunodeficiency virus infected asymptomatic carriers. Vet. Immunopathol. 1992;35:15–22. doi: 10.1016/0165-2427(92)90117-9. [DOI] [PubMed] [Google Scholar]
  7. Kensil C.R., Barrett C., Kushner N., Beltz G., Storey J., Recchia J., Aubert A., Marciani D. Development of a genetically engineered vaccine against feline leukemia virus infection with FeLV. J. Am. Vet. Med. Assoc. 1991;199:1423–1427. [PubMed] [Google Scholar]
  8. Lehmann R., Franchini M., Aubert A., Wolfensberger C., Cronier J., Lutz H. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine. J. Am. Vet. Med. Assoc. 1991;199:1446–1452. [PubMed] [Google Scholar]
  9. Lehmann R., Beust B., Niederer E., Condrau M.A., Fierz W., Aubert A., Ackley C.D., Cooper M.D., Tompkins M.B., Lutz H. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus. Vet. Immunol. Immunopathol. 1992;35:199–214. doi: 10.1016/0165-2427(92)90132-a. [DOI] [PubMed] [Google Scholar]
  10. Lutz H., Pedersen N.C., Durbin R., Theilen G.H. Monoclonal antibodies to three epitopic regions of feline leukemia virus p27 and their use in enzyme-linked immunosorbent assay of p27. J. Immunol. Methods. 1983;56:208–221. doi: 10.1016/0022-1759(83)90413-1. [DOI] [PubMed] [Google Scholar]
  11. Lutz H., Arnold P., Hübscher U., Egberink H., Pedersen N., Horzinek M.C. Specificity assessment of feline T-lymphotropic lentivirus serology. J. Vet. Med. B. 1988;35:773–778. doi: 10.1111/j.1439-0450.1988.tb00559.x. [DOI] [PubMed] [Google Scholar]
  12. Lutz H., Lehmann R., Winkler G., Kottwitz B., Dittmer A., Wolfensberger C., Arnold P. Das feline Immunschwächevirus in der Schweiz: Klinik und Epidemiologie im Vergleich mit dem Leukämie- und dem Coronavirus. Schweiz. Arch. Tierheilkd. 1990;132:217–225. [PubMed] [Google Scholar]
  13. Marciani D.J., Kensil C.R., Belts G.A., Hung C.H., Cronier J., Aubert A. Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine. 1991;9:89–96. doi: 10.1016/0264-410x(91)90262-5. [DOI] [PubMed] [Google Scholar]
  14. Pollock R.V., Scarlett J.M. Randomized blind trial of a commercial FeLV vaccine. J. Am. Vet. Med. Assoc. 1990;196:611–616. [PubMed] [Google Scholar]
  15. Prince H.E., Bermudez S., Plaeger-Marshall S. Preparation of CD8bright and CD8dim lymphocyte populations using two positive selection methods in tandem. J. Immunol. Methods. 1993;165:139–148. doi: 10.1016/0022-1759(93)90339-9. [DOI] [PubMed] [Google Scholar]
  16. Reinacher M., Theilen G. Frequency and significance of feline leukemia virus infection in necropsied cats. Am. Vet. Res. 1987;48:939–945. [PubMed] [Google Scholar]
  17. Sachs L., editor. Angewandte Statistik. Springer; Berlin: 1984. [Google Scholar]
  18. Theilen G.H., Kawakami T.G., Rush J.D., Munn R.J. Replication of cat leukemia virus in cell suspension cultures. Nature. 1969;222:589–590. doi: 10.1038/222589b0. [DOI] [PubMed] [Google Scholar]
  19. Torten M., Franchini M., Barlough J.E., George J.W., Mozes E., Lutz H., Pedersen N.C. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J. Virol. 1991;65:2225–2230. doi: 10.1128/jvi.65.5.2225-2230.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Veterinary Immunology and Immunopathology are provided here courtesy of Elsevier

RESOURCES